COVID-19 Survey report: The Lasting Impact on Outsourcing Decisions

We conducted a blind and independent “voice of the customer” industry survey in late Q4 2020 and into Q1 2021 with the opt-in online readership of Contract Pharma to ascertain what impact COVID-19 had – and was continuing to have – on outsourcing decisions for those who sought CRO, CDMO, or both CRO and CDMO services in the global pharmaceutical industry.

The insights provided by survey respondents reveal what happened within the outsourcing industry in 2020, where it’s going in 2021, and the role COVID-19 played in dramatically shifting attitudes, preferences and actions within the global pharmaceutical supply chain.

Here is a sample of some of the questions the report’s respondents answer in often unexpected ways:

  • What “normal” CRO/ CDMO outsourcing processes and buying decisions were impacted the most? 
  • Which CRO/CDMO services were most difficult to resource? 
  • What percentage of respondents are looking for new CRO/CDMO partners within the next twelve months? 
  • How many respondents are expressing a preference for US-based CRO/CDMO partners?
  • How much of their outsourcing work do they plan to shift because of COVID-19 and other supply chain concerns?

Download the report to see these answers and much more.



Request Free!